Prof. Andrew X. Zhu is Director of Jiahui International Cancer Center, Director Emeritus of Liver Cancer Research at Massachusetts General Hospital Cancer Center, and Professor of Medicine at Harvard Medical School. The major focus of his research is to develop more effective therapies for hepatocellular carcinoma (HCC) and cholangiocarcinoma.
As a widely published author, Dr. Zhu has served as a principal investigator in many clinical trials in HCC, cholangiocarcinoma and other gastrointestinal cancers. An internationally recognized leader in HCC and cholangiocarcinoma, he led the pivotal studies of developing several molecularly targeted, immunotherapeutic agents, and combination regimens in liver cancers which led to regulatory approval and studying the predictive and surrogate molecular and imaging biomarkers. He and his colleagues initially identified the presence of IDH mutations and the resistance mechanism to FGFR inhibitor in cholangiocarcinoma. He is a founding member of the International Liver Cancer Association, Fellow of American College of Physicians, and a member of ASCO and AACR. Dr. Zhu has served on the Hepatobiliary Cancer committee of the National Comprehensive Cancer Network, the Grants Selection Committee of ASCO, the Hepatobiliary Cancer Task Force of The NCI Gastrointestinal Cancer Steering Committee, the American Joint Committee on Cancer Hepatobiliary Task Force, the Hepatocellular Carcinoma Practice Guidelines Committee of the American Association for the Study of Liver Diseases, and the Clinical Advisory Board of The Cholangiocarcinoma Foundation. He has received several awards for his work, including V Foundation Translational Research Award, Lorenzo Cappussotti Award, and Jonathan Kraft Translational Award.